Advance Search
YAN Zeying, SUN Haimin, CHEN Yu. Clinical observation of venetoclax in treatment of relapsed or refractory acute myeloid leukemia[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 91-94. DOI: 10.7619/jcmp.20214194
Citation: YAN Zeying, SUN Haimin, CHEN Yu. Clinical observation of venetoclax in treatment of relapsed or refractory acute myeloid leukemia[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 91-94. DOI: 10.7619/jcmp.20214194
shu

Clinical observation of venetoclax in treatment of relapsed or refractory acute myeloid leukemia

  • Department of Hematology, Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai, 200025

More Information
  • Received Date: October 25, 2021
  • Available Online: March 10, 2022
  • Published Date: February 14, 2022
    Graphical Abstract
    • Abstract
  •   Objective  To observe the efficacy of venetoclax combined with hypomethylated drugs in the treatment of relapsed or refractory acute myeloid leukemia (AML).
      Methods  Clinical materials of 14 patients with relapsed or refractory AML in the Department of Hematology of the Northern Branch of Ruijin Hospital Affiliated to the Medical College of Shanghai Jiaotong University from January 2020 to August 2021 were analyzed retrospectively and followed up. Ten patients were treated with venetoclax and azacytidine, and the other four patients were treated with venetoclax and decitabine.
      Results  There were 5 cases with curative effect of complete remission (CR) or morphological CR with incomplete recovery of platelet count (CRi), 3 cases with partial remission (PR) and 6 cases with no remission (NR). Bone marrow suppression occurred in all the patients after treatment, and pulmonary infection was observed in 6 cases.
      Conclusion  The prognosis of patients with relapsed or refractory AML is poor. Venetoclax combined with hypomethylated drugs has a significant effect in some patients, which can achieve the CR result, and has better tolerance.
    • FullText(HTML)
    • References (23)
  • [1]
    DINARDO C D, RAUSCH C R, BENTON C, et al. Clinical experience with the Bcl-2inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies[J]. American Journal of Hematology, 2018, 93(3): 401-407. doi: 10.1002/ajh.25000
    [2]
    BYRNE M, DANIELSON N, SENGSAYADETH S, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia[J]. American Journal of Hematology, 2020, 95: 1006-1014. doi: 10.1002/ajh.25859
    [3]
    BEWERSDORF J P, GIRI S, WANG R, et al. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis[J]. Haematologica, 2020, 105(11): 242826.
    [4]
    DINARDO C D, JONAS B A, PULLARKAT V, et al. Azacitidine and venetoclax in Previously Untreated Acute Myeloid Leukemia[J]. New England Journal of Medicine, 2020, 383(7): 617-629. doi: 10.1056/NEJMoa2012971
    [5]
    DINARDO C D, PRATZ K, POTLURI J, et al. Durable Response with venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)[J]. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18(Suppl 1): S201.
    [6]
    MEI M, ALDOSS I, MARCUCCI G, et al. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use[J]. American Journal of Hematology, 2019, 94(3): 358-362.
    [7]
    AGARWAL S, GOPALAKRISHNAN S, MENSING S, et al. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis[J]. Hematological Oncology, 2019, 37(4): 464-473. doi: 10.1002/hon.2646
    [8]
    JONES A K, FREISE K J, AGARWAL S K, et al. Clinical Predictors of venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis[J]. Aaps Journal, 2016, 18(5): 1-11.
    [9]
    SALEM A H, DAVE N, MARBURY T, et al. Pharmacokinetics of the Bcl-2 Inhibitor venetoclax in Subjects with Hepatic Impairment[J]. Clinical Pharmacokinetics, 2019, 58(8): 1091-1100. doi: 10.1007/s40262-019-00746-4
    [10]
    FREISE K J, SHEBLEY M, SALEM A H. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model[J]. Journal of Clinical Pharmacology, 2017, 57(6): 796-804. doi: 10.1002/jcph.858
    [11]
    HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646. doi: 10.1016/j.cell.2011.02.013
    [12]
    WONG R S. Apoptosis in cancer: from pathogenesis to treatment[J]. Journal of Experimental & Clinical Cancer Research, 2011, 30(1): 87-87.
    [13]
    PFEFFER C M, ATK S. Apoptosis: A Target for Anticancer Therapy[J]. International Journal of Molecular Sciences, 2018, 19(2): 448-454. doi: 10.3390/ijms19020448
    [14]
    CROCE C M, REED J C. Finally, An Apoptosis-Targeting Therapeutic for Cancer[J]. Cancer Research, 2016, 76(20): 5914-5920. doi: 10.1158/0008-5472.CAN-16-1248
    [15]
    PRONIER E, ROSS L L. IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AMLs armour[J]. Cancer cell, 2015, 27(3): 323-325. doi: 10.1016/j.ccell.2015.02.013
    [16]
    MA J, ZHAO S J, QIAO X A, et al. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia[J]. Clin Cancer Res, 2019, 25(22): 6815-6826. doi: 10.1158/1078-0432.CCR-19-0832
    [17]
    ZHOU J D, ZHANG T J, XU Z J, et al. BCL-2 overexpression: clinical implication and biological insights in acute myeloid leukemia[J]. Diagnostic Pathology, 2019, 14(1): 68. doi: 10.1186/s13000-019-0841-1
    [18]
    STONE R M, MANDREKAR S J, SANFORD B L, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation[J]. N Engl J Med, 2017, 377(5): 454-454. doi: 10.1056/NEJMoa1614359
    [19]
    CORTES J E, SMITH B D, WANG E S. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS Phase 2 study results[J]. Npj Precision Oncology, 2018, 93(11): 1301-1310.
    [20]
    RAVANDI F, ASSI R, DAVER N, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study[J]. The Lancet Haematology, 2019, 6(9): e480-e488. doi: 10.1016/S2352-3026(19)30114-0
    [21]
    PETERSDORF S H, KOPECKY K J, SLOVAK M, et al. A phase 3 study of gemtuzumabozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia[J]. Blood, 2013, 121(24): 4854-4860. doi: 10.1182/blood-2013-01-466706
    [22]
    CHONG C, ROBERTS A W, REYNOLDS J, et al. Chemotherapy and venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of venetoclax Combined With Modified Intensive Chemotherapy[J]. Journal of Clinical Oncology, 2020, 38(30): 3506-3517. doi: 10.1200/JCO.20.00572
    [23]
    ZHANG J, GU Y, CHEN B. Mechanisms of drug resistance in acute myeloid leukemia[J]. Onco Targets and therapy, 2019, 12: 1937-1945. doi: 10.2147/OTT.S191621
    • Related Articles

  • Related Articles

    [1]LAI Yanling, CAI Dongmei, ZHUO Jingjing, LI Hao, LI Wenhui. Risk factors for postoperative secondary hydrocephalus in patients with severe craniocerebral injury and construction of nomogram risk model[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 94-97, 117. DOI: 10.7619/jcmp.20242442
    [2]WANG Wang, ZHAO Han. Construction of a nomogram prediction model for catheter-related bloodstream infections in hemodialysis patients with chronic renal failure[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 95-100. DOI: 10.7619/jcmp.20240464
    [3]REN Weiwei, WANG Chao, MENG Junhua, XU Suhong. Establishment and validation of an individualized risk prediction nomogram model for gestational diabetes mellitus in pregnant women with hypothyroidism[J]. Journal of Clinical Medicine in Practice, 2024, 28(16): 93-97. DOI: 10.7619/jcmp.20234265
    [4]WANG Huili, LI Huijuan, LU Yan, QIN Xiuyu, CHEN Dandan, XU Yun. Risk factors of intraoperative hypothermia in patients undergoing radical thyroidectomy under laparoscopy and the construction of nomogram model[J]. Journal of Clinical Medicine in Practice, 2024, 28(4): 29-33. DOI: 10.7619/jcmp.20232740
    [5]SONG Feng, FANG Canjun, HU Jing, CHEN Yi. Risk factors of preoperative deep venous thrombosis in young and middle-aged patients with hip fracture and construction of a Nomogram predictive model[J]. Journal of Clinical Medicine in Practice, 2023, 27(12): 32-37. DOI: 10.7619/jcmp.20230579
    [6]YI Yanan, HAN Chongxu, LIANG Chengtong, YANG Mingyu, WANG Mengting. Risk factors identification for prognosis of ovarian cancer patients with lung metastasis and establishment of nomogram[J]. Journal of Clinical Medicine in Practice, 2023, 27(1): 1-8, 15. DOI: 10.7619/jcmp.20223123
    [7]DONG Yanping, WANG Jiemin, WANG Yujin, REN Yali, DONG Yucheng, YONG Yanjun, SU Xuandi, WANG Jixiang, SU Nan, WANG Fuli, XIA Duosheng. Construction and evaluation of Nomogram prediction model for postoperative recurrence of pterygium[J]. Journal of Clinical Medicine in Practice, 2022, 26(7): 52-56. DOI: 10.7619/jcmp.20214610
    [8]ZHOU Lanmei, JIANG Lijun, ZHU Fengxia, ZHAO Xuemei, JIN Yanting. Analysis in risk factors of respiratory tract infectionin preschool children and construction of nomogram prediction model[J]. Journal of Clinical Medicine in Practice, 2021, 25(14): 9-14. DOI: 10.7619/jcmp.20211520
    [9]HU Tingting, GUO Qiu, TANG Weiwei, YANG Huan, LIU Guijun. A Nomogram model establishment for noscomial infection in elderly patients with hypertension and diabetes mellitus[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 55-60. DOI: 10.7619/jcmp.20210055
    [10]ZHANG Zhen, ZHANG Hengzhu, LI Yuping, YAN Zhengcun, DONG Lun, WANG Xiaodong, WANG Xingdong. Relationship between systemic inflammation response index and symptomatic cerebral vasospasm after aneurismal subarachnoid hemorrhage as well as construction of a Nomogram predictive model[J]. Journal of Clinical Medicine in Practice, 2020, 24(10): 36-40. DOI: 10.7619/jcmp.202010009

  • Cited by

    Periodical cited type(64)

    1. 李秀燕. SWOT多学科协作下康复护理在急性脑梗死患者恢复期中的效果. 基层医学论坛. 2025(02): 118-121 .
    2. 蒋渊，吴芳芳. 补阳还五汤联合丁苯酞软胶囊治疗急性脑梗死气虚血瘀证的效果及对血液流变学的影响. 临床合理用药. 2025(05): 50-53 .
    3. 延艳斌，刘文文. 益气通络汤联合针灸治疗气虚血瘀证缺血性脑卒中对患者血液流变学、神经功能的影响. 中国基层医药. 2025(01): 47-52 .
    4. 王亚宽，赵京伟，陈秋云，刘忠杰，刘中一，刘洁琼，郭泉滢，王明. 益气通脉方联合常规西药治疗H型高血压合并急性缺血性脑卒中临床研究. 新中医. 2025(05): 60-63 .
    5. 朱钦辉，陈丹霞，魏统国. 替罗非班联合直接取栓对急诊急性脑梗死患者血管再通率影响的临床研究. 陕西医学杂志. 2024(01): 95-98+103 .
    6. 常虹，李雁翔，王琳，吴小玉. 依洛尤单抗联合阿替普酶治疗急性脑梗死的临床研究. 现代药物与临床. 2024(01): 106-110 .
    7. 韩娟，宋彦，李旭，韩悦，张辉. 血脂康胶囊联合曲克芦丁治疗动脉粥样硬化血栓性脑梗死的临床研究. 现代药物与临床. 2024(02): 357-361 .
    8. 刘玉川. 补阳还五汤配合康复训练治疗脑卒中偏瘫临床观察. 实用中医药杂志. 2024(02): 204-206 .
    9. 张茹茵，刘洁，孟灵娜. 依达拉奉右莰醇结合阿替普酶溶栓对急性脑梗死患者脑血流动力学及颈动脉超声指标的影响. 罕少疾病杂志. 2024(02): 17-18 .
    10. 樊丽娜，黄超异，吴春红，任延婷，何艳秋. 多学科共管模式联合超早期回授法康复教育在急性缺血性脑卒中介入治疗后卧床患者中的应用. 国际护理学杂志. 2024(04): 612-616 .
    11. 邓华云. 多元化激励干预在重型脑外伤合并高血压护理中的应用效果. 中外医学研究. 2024(05): 91-94 .
    12. 步红静，马娜，张盼盼，刘远洪. 急性穿支动脉脑梗死患者早期神经功能恶化列线图的建立与验证. 中国卒中杂志. 2024(02): 158-166 .
    13. 徐梦诗. 阿加曲班联合依达拉奉右崁醇对急性脑梗死患者的临床疗效研究. 现代医学与健康研究电子杂志. 2024(04): 13-15 .
    14. 马春红，王珂，相闽. 血浆同型半胱氨酸、血清碱性磷酸酶、D二聚体在高血压合并脑梗死患者中的表达及临床意义研究. 临床研究. 2024(04): 112-115 .
    15. 郭蕊，程慧敏，史丽君，凌孝征. 围手术期HIF-1α、ANGPTL2、SDF-1与大面积脑梗死去骨瓣减压术后病情转归的相关性分析. 河南医学研究. 2024(04): 637-640 .
    16. 姚先丽，李坤彬，刘亚鸽，温小鹏，吴志远，焦冰. 补阳还五汤加减联合脑-肢协同调控治疗卒中后肢体功能障碍临床研究. 新中医. 2024(07): 36-41 .
    17. 赵静静. 天麻素注射液辅治缺血性脑卒中临床观察. 实用中医药杂志. 2024(03): 469-471 .
    18. 刘玉川. 天麻钩藤饮辅治脑出血临床观察. 实用中医药杂志. 2024(03): 503-505 .
    19. 康敏毅，梁康. 血清同型半胱氨酸、维生素B12及血尿酸水平与脑梗死的相关性. 贵州医药. 2024(04): 585-587 .
    20. 肖玉平，刘新科，杨晓光，肖夏，崔啸天. 老年急性脑梗死患者血清lncRNA XIST和lncRNA SOX2OT水平及其预后价值. 热带医学杂志. 2024(04): 541-545 .
    21. 杜娟，陈园园. 血清Hcy、UA、CRP水平与急性脑梗死合并T2DM患者病情的关系. 中国急救复苏与灾害医学杂志. 2024(05): 603-606 .
    22. 魏守元，耿涛，刘龙生. 手术导航定位系统在高血压脑出血穿刺引流中的应用. 中国医学创新. 2024(14): 27-31 .
    23. 陈彬，黎希年，张勇. 化痰通络汤对急性脑梗死血管内治疗再灌注临床研究. 中外医学研究. 2024(14): 103-107 .
    24. 王茜，全咏莉，徐莉. 医联体背景下系统化护理对脑卒中患者肢体功能、神经缺损及照顾者心理弹性的影响. 临床医学研究与实践. 2024(19): 153-156 .
    25. 张俊冬，杨玉锋，李建波，郭芳莉. 盐酸替罗非班联合丁苯酞注射液对穿支动脉脑梗死患者临床预后的影响. 中国药物与临床. 2024(09): 579-583 .
    26. 王亮亮，韩若东，张亚飞，吴国柱，徐彦龙. 急性脑梗死患者入院时Hcy、HMGB1、TLR4水平与单核巨噬细胞极化的相关性. 检验医学与临床. 2024(14): 1996-2000 .
    27. 郭琳. 脑钠肽、同型半胱氨酸测定在急性脑梗死诊治中的作用. 中国基层医药. 2024(06): 869-873 .
    28. 郑小玲. 系统性阶梯式康复干预措施对硬膜外血肿术后患者的影响. 中外医学研究. 2024(20): 119-122 .
    29. 秦慧兵，刘红钊，程曼. 脑脊液β-EP, 3-NT水平与脑胶质瘤患者术后神经损伤程度及预后的关系研究. 实用癌症杂志. 2024(09): 1453-1456 .
    30. 王绪耀，王水雨，崔嬿嬿. 护理流程优化路径对急性缺血性脑卒中静脉溶栓的影响. 岭南急诊医学杂志. 2024(04): 405-407 .
    31. 刘磊，张洁茹，郑丽，贾丹，冯裕广. 复方脑蛋白水解物片联合丁苯酞治疗急性脑梗死后认知功能障碍的疗效分析. 新疆医科大学学报. 2024(09): 1226-1230+1236 .
    32. 李海荣，温晓强. 曲克芦丁脑蛋白水解物联合尤瑞克林、丁苯酞治疗缺血性脑卒中的效果及对神经因子水平的影响. 临床医学研究与实践. 2024(27): 38-41 .
    33. 赖涛. 颅内血肿穿刺引流与开颅血肿清除骨瓣治疗高血压脑出血患者对比研究. 中外医学研究. 2024(27): 76-79 .
    34. 魏玲，凌日华. 苏合香丸联合依达拉奉对急性脑梗死患者神经功能及日常生活自理能力的影响. 云南中医中药杂志. 2024(10): 54-56 .
    35. 蔡兰英，高玲艳. 小续命汤加减联合丁苯酞氯化钠注射液治疗风痰入络证急性脑梗死患者的效果观察. 大医生. 2024(20): 71-74 .
    36. 贾佳. 血府逐瘀汤辅治脑卒中后偏瘫气虚血瘀型临床观察. 实用中医药杂志. 2024(10): 1945-1948 .
    37. 韦红艳，庞可心，刘艳梅. 芪龙活络方联合阿托伐他汀治疗脑梗死恢复期(气虚血瘀证)的疗效及对颈动脉粥样硬化斑块和血清脂蛋白、Hcy水平的影响. 中国医师杂志. 2024(10): 1572-1576 .
    38. 郭路路，何梦娟，罗琼蕾，丁孟丽. 基于聚类分析的多维照护策略在ICU急性脑梗死患者中的应用. 齐鲁护理杂志. 2024(21): 76-79 .
    39. 夏玲玲，常红娟，孟欣，陈燕. 急性脑梗死患者“血清同型半胱氨酸、小而低密度脂蛋白、低密度脂蛋白”水平变化及其临床意义分析. 辽宁医学杂志. 2024(06): 64-68 .
    40. 赵辉，娄茜. 血清糖脂代谢指标和同型半胱氨酸联合检测对急性脑梗死病情进展的评价价值. 临床检验杂志. 2024(12): 913-916 .
    41. 田忠琳. 肌肉电刺激联合运动表象训练治疗对脑卒中患者神经功能及步行能力的影响. 反射疗法与康复医学. 2024(19): 49-52 .
    42. 杨杰. 气垫床联合曲线型仰卧护理对高血压脑出血患者去骨瓣减压术后压力性损伤及预后的影响. 医学理论与实践. 2023(02): 311-313 .
    43. 周让. 急性缺血性脑卒中患者的血清神经元特异性烯醇化酶及淀粉样蛋白A、C-反应蛋白水平与脑损伤、梗死程度的相关性分析. 现代医学与健康研究电子杂志. 2023(03): 93-96 .
    44. 汪宁，彭兆快. 颈动脉超声定量参数联合miR-128-3p诊断急性脑梗死的研究. 影像科学与光化学. 2023(01): 109-113 .
    45. 王秀杰，熊鑫，李敏，范海燕，郑富霞，赵晓晶. 急性轻中度脑梗死患者血浆脂蛋白磷脂酶A2水平升高的影响因素. 山东医药. 2023(03): 55-57 .
    46. 田竟，张杨. SWOT分析法联合急救护理流程优化在急性脑梗死患者救护中的应用. 河南医学研究. 2023(02): 344-347 .
    47. 周丹，李秀丽，胡浩，翟少朋，王满侠. 卵圆孔未闭相关卒中的诊断性生物标志物的临床价值. 实用临床医药杂志. 2023(02): 134-138 . 本站查看
    48. 景良，许学杰，舒艳，罗军. 椎基底动脉延长扩张症伴急性卒中预后的相关因素研究. 大医生. 2023(05): 111-113 .
    49. 梁文俊，严梓乐，吴卫娟，孙玙，杨水泉. 大动脉粥样硬化型与心源型急性缺血性脑卒中患者脑缺血状态及血管内治疗效果的差异性分析. 中国医师杂志. 2023(02): 288-291 .
    50. 牛津，杨振博. 丁苯酞对急性脑梗死患者疗效、生化指标及外周血单核细胞Toll样受体4 mRNA表达的影响. 现代医学与健康研究电子杂志. 2023(07): 33-35 .
    51. 张晓娟，刘松涛，韩荦杰，贺英，许珊珊，刘海港，冯倩，张莉. 养血清脑颗粒联合氟哌噻吨美利曲辛治疗中风后抑郁对患者单胺类神经递质的影响. 现代医学与健康研究电子杂志. 2023(07): 17-20 .
    52. 黎灵锋，温应方，谢燕芳. 脂蛋白相关磷脂酶A2、同型半胱氨酸、红细胞分布宽度在H型高血压伴急性脑梗死患者中的应用价值. 黑龙江医学. 2023(11): 1356-1358 .
    53. 吴小萍，马龙，武玮，桑媛媛，梁海. 脉管复康胶囊联合尼麦角林治疗脑梗死后认知障碍瘀血内阻证的临床效果. 中国医药导报. 2023(17): 86-89 .
    54. 敖良，游娟，钟利波. 高血压脑出血患者血清Hcy、CRP与病情严重程度的相关性分析. 华夏医学. 2023(04): 72-76 .
    55. 李桂英，陈娟. 早期预警评分在静脉溶栓桥接动脉取栓急性脑梗死患者护理中的应用. 护理实践与研究. 2023(16): 2455-2459 .
    56. 刘燕霞，郭琳佳，孙海燕. 同型半胱氨酸、碱性磷酸酶及N端-B型钠尿肽前体与急性脑梗死静脉溶栓短期预后的关系. 实用医院临床杂志. 2023(06): 61-64 .
    57. 钟曌，郭继勃，郭昊，韩晓婷，张丽萍，祝刚. 急性缺血性脑卒中患者血清Kruppel样转录因子2水平表达与脑梗死体积及预后的相关性研究. 现代检验医学杂志. 2023(06): 1-5+12 .
    58. 张彦朋，张向东，杨新丽，孙九艳. 脑梗死急性期降压治疗对预后的影响. 中国医学工程. 2023(12): 123-126 .
    59. 李华伟. 依达拉奉右莰醇联合丁苯酞氯化钠注射液治疗急性脑梗死患者的效果. 中国民康医学. 2023(23): 31-34 .
    60. 禹晓燕. 阿替普酶与丁苯酞联合间歇充气加压治疗急性脑梗死的效果观察. 华夏医学. 2023(06): 130-134 .
    61. 渠林楠，江艳，席晓玲，刘波，孙晓虹，韩雷. 健康体检人群中高同型半胱氨酸血症患者发生高血压影响因素分析. 中华保健医学杂志. 2023(05): 597-598+601 .
    62. 陈丽琴，毛琴，郑毓卿. 家庭康复护理结合积极心理干预对脑卒中患者及家庭照护者的影响分析. 现代诊断与治疗. 2023(19): 2974-2976 .
    63. 赖智宗，叶伟胜，黄勇明. 胞磷胆碱钠联合依达拉奉右莰醇治疗急性缺血性脑卒的临床疗效观察. 现代诊断与治疗. 2023(20): 3052-3054 .
    64. 许家华，陈丹. 拉莫三嗪与丙戊酸钠联合治疗脑卒中继发性癫痫的临床效果. 实用中西医结合临床. 2022(20): 53-55 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML
    Article views (270) PDF downloads (21) Cited by(67)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return